Urothelial Carcinoma
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer [Phase 2]
This clinical trial update describes a Phase 2 neoadjuvant treatment using an immune checkpoint inhibitor for urothelial carcinoma. Recruitm…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study) [NA]
A clinical trial is recruiting to evaluate a urine tumor DNA panel for screening urothelial cancer in individuals with Lynch syndrome (LS-UR…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression [Phase 1, Phase 2]
Clinical trial update for BT5528-100 (Phase 1/2) in EphA2-expressing advanced solid tumors. The study includes urothelial carcinoma, ovarian…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer [NA]
PROMOTE is a UCSF-sponsored clinical trial aiming to identify predictive markers of response in genitourinary cancers, including prostate ca…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery [Phase 1, Phase 2]
A Phase 1/2 trial evaluating ixazomib citrate with gemcitabine and doxorubicin for metastatic or unresectable urothelial carcinoma; the stud…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Sacituzumab Govitecan Plus EV in Metastatic UC [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating sacituzumab govitecan in combination with Enfortumab Vedotin for metastatic urothelial cancer; the …
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Clinical trial INSITE investigates pre-surgical identification of muscle-invasive tumor involvement in patients with urothelial carcinoma sc…
-
CLINICAL_TRIALS withdrawal · 2025-10-21Clinical Trial Update: Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial [Phase 2]
The NERA trial, a Phase 2 study of erdafitinib with or without atezolizumab in localized bladder cancer patients ineligible for cisplatin ch…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describing safety, tolerability, and imaging with [68Ga]Ga-DPI-4452 and safety, tolerability, and efficacy…
-
FDA approval · 2025-10-17FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for BALVERSA (erdafitinib) from Janssen Products LP.
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial of INCB099318 in participants with advanced solid tumors has been terminated. The update reports safety, tolerability…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
A prospective validation trial evaluating high-volume urine DNA testing in individuals with suspected urothelial carcinoma.
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma [Phase 1, Phase 2]
A Phase 1/2 neoadjuvant trial is evaluating PD-1 blockade plus TIGIT blockade in cisplatin-ineligible operable high-risk urothelial carcinom…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors [Phase 2]
This document provides an update on the Phase 2 trial of pemigatinib in non-muscle invasive bladder cancer patients with recurrent low- or i…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors [Phase 2]
Phase 2 clinical trial update for BL-B01D1 in patients with multiple solid tumors, including locally advanced or metastatic urinary system t…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors [Phase 2]
A Phase 2 study evaluating SI-B003 alone and in combination with BL-B01D1 in patients with locally advanced or metastatic urothelial carcino…
-
EMA approval · 2025-09-25EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
The European Medicines Agency authorised Padcev (enfortumab vedotin) for urothelial carcinoma and other urologic neoplasms in the European U…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma [Phase 2]
Phase 2 trial evaluating talazoparib in combination with avelumab as maintenance therapy for platinum-sensitive urothelial carcinoma is curr…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Registry Platform Urologic Cancer
An ongoing clinical trial update from iOMEDICO AG describing a recruiting study for renal cell carcinoma and urothelial carcinoma.
-
CLINICAL_TRIALS trial_result · 2025-09-17Clinical Trial Update: A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors [Phase 1]
Pfizer's PF-07820435 study in advanced solid tumors, including non-small-cell lung cancer and other indications, has been terminated at Phas…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
A clinical trial is evaluating the combination of PD-1/PD-L1 immune checkpoint inhibitors with radiotherapy across several cancers to assess…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients [NA]
A clinical trial update describes evaluating compression stockings to prevent chemotherapy-induced peripheral neuropathy caused by antibody-…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors [Phase 1]
Phase 1a/1b study of TPST-1495 as monotherapy and in combination with pembrolizumab has completed status, spanning multiple solid tumors inc…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating pembrolizumab plus enfortumab vedotin, with or without investigational age…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
This clinical trial update describes a Duke University study evaluating immune-based biomarkers and circulating tumor cells in patients trea…